Quantum computing for drug discovery and biology: Junction Brief – November 2026

Acentric Research is produced with AI tools under human review. The authors are not financial professionals, and nothing here is investment advice or a recommendation to buy or sell any security. AI analysis can be wrong; check every claim against its cited source.

This Brief is an initial scan, not a full investigation. The method and scores behind it are in Biotechnology × Quantum in the Landscape Report.

Overview

Drug design depends on knowing how molecules behave. A 2019 review says quantum computers promise efficient, accurate results for problems such as the electronic structure of molecules, and that is why researchers are studying them. [1] The sources opened describe the field as early.

What stands out is the gap between funding and results. Governments, a charity and start-ups are named as funders or recipients in the sources opened, and one drugmaker is named as a participant, while the sources opened report estimates and plans, not a drug-related calculation that conventional computers cannot do. The dated sources opened run from 2019 to 2025 and most are from 2019 to 2024; later developments, including 2025–26 news on quantum computing for drugs, were not searched.

Current state

What the technology would do. The 2022 perspective by Blunt and colleagues, whose abstract was read, estimates the quantum computing cost of simulating parts of a drug-protein complex involving the drug ibrutinib. It says the calculations need an error-corrected quantum architecture and that newer algorithms cut the estimated time for a 50-orbital problem from over 1,000 years to a few days. [2] These are estimates for an error-corrected quantum architecture that the perspective describes.

Public programs. NIH's Office of Data Science Strategy runs a quantum computing program aimed at disease modeling, drug development, personalized medicine and data-driven health care; its page lists a joint Department of Energy and NIH roundtable report, an innovation lab and the Qu-BIT program (NCATS's Quantum Biomedical Innovations and Technologies program). [3][4] The National Center for Advancing Translational Sciences runs a Quantum Computing Challenge with a purse of up to $1.3 million over two stages, covering algorithms for drug discovery, clinical risk prediction and imaging; it reports winning teams receiving $125,000 for their first-milestone submissions. [4] The UK programme says the quantum computing technologies being worked on are "very much in their infancy". [5]

Funded projects. SEEQC UK reported a £6.85 million Innovate UK grant in 2021 to build a quantum computer for pharmaceutical development for Merck, aimed at simulating light-activated cancer drugs. [6] A team at the University of Nottingham with Phasecraft and QuEra was awarded over £1 million by Wellcome Leap's Quantum for Bio program in 2024 to study covalent inhibitors for myotonic dystrophy. [7] POLARISqb reported a DARPA research contract to develop a quantum algorithm for molecules that act on protein-protein interactions. [8] SEEQC's release says its computer would run a simulation within 18 months, with Merck benchmarking the machine to judge its commercial viability, and that the machine would be the first integration of a quantum computer with a high-performance computer on one network (company claims); no report of the result was found in the sources opened. [6] All are announcements, in trade press reproducing releases.

What the review literature says. A 2019 review of quantum chemistry on quantum computers says these machines promise to deliver accurate results efficiently for problems such as the electronic structure of molecules, and presents the algorithms and results then available (abstract read; the full text was not read). [1] The UK programme describes its quantum computing hub as a collaboration of 17 universities and says possible gains for drug development are some way off. [5]

How far it has come. Research and planning. The sources opened name no quantum calculation that gave a drug design result conventional computing could not, and no drug in development credited to one. [2][6][7][8]

Opportunities

Merck, the drugmaker the SEEQC project was built for, is quoted in the release as looking forward to being an early adopter, which is the one drugmaker statement found. [6] If error-corrected quantum computers arrive, the perspective estimates that calculations in active spaces of about 50 orbitals could take a few days. [2] The Nottingham project combines quantum computing with classical simulation methods; its release says its aim is to show that quantum computing could have real-world impact in treating disease. [7] NCATS names three areas for its prize challenge, drug discovery algorithms, clinical risk prediction and diagnosis, and imaging and genomic data analysis, so the work reaches beyond molecule design. [4] The 2021 SEEQC project is aimed at simulating photosensitizing drugs for light-activated cancer treatment, which the release says useful simulations cannot do with classical computing alone (company claim). [6]

Challenges

  • Physics and engineering. The estimates assume an error-corrected quantum architecture. [2] SEEQC's plan calls for a custom cryostat and a redesigned refrigerator that cools at multiple levels, and its release says the project needed bespoke components. [6] The UK programme says the technologies are in their infancy. [5]
  • Capital and scale-up. The announced awards run from over £1 million to £6.85 million; the sources opened do not report quantum-computing revenue from drugmakers. [6][7]

Data sources

  • NIH program and prize-challenge pages, for federal activity. [3][4]
  • NIH RePORTER, for grants. [9]
  • SEC EDGAR, for company filings that mention quantum projects. [10]
  • Europe PMC, for the research literature. [11]
  • ClinicalTrials.gov, for any drug candidate attributed to quantum methods. [12]
  • No registry of quantum-computing drug projects was found; announcements are the main record.

Changelog

  • 2026-11-18: First published.

Sources

  1. Yudong Cao and others, "Quantum Chemistry in the Age of Quantum Computing", Chemical Reviews, 2019, abstract (Europe PMC record, PMID 31469277; the full text was not read). ebi.ac.uk (accessed 2026-11-18)
  2. Nicholas S. Blunt and others, "Perspective on the Current State-of-the-Art of Quantum Computing for Drug Discovery Applications", Journal of Chemical Theory and Computation, 2022, abstract (Europe PMC record, PMID 36355616; the full text was not read). ebi.ac.uk (accessed 2026-11-18)
  3. NIH Office of Data Science Strategy, "NIH/ODSS Quantum Computing Program" (agency page, last reviewed 2025-12-30). datascience.nih.gov (accessed 2026-11-18)
  4. National Center for Advancing Translational Sciences, "Quantum Research Activities" (agency page). ncats.nih.gov(accessed 2026-11-18)
  5. UK National Quantum Technologies Programme, "Four ways quantum technologies are advancing the future of healthcare", 2022-05-24 (programme statement). uknqt.ukri.org (accessed 2026-11-18)
  6. The Quantum Insider, "SEEQC UK Awarded £6.8M Innovate UK Grant to Build Enterprise-Level Quantum Enhanced Computer for Pharmaceutical R&D", 2021-11-05 (trade press reproducing a company press release; plans and claims are the company's). thequantuminsider.com (accessed 2026-11-18)
  7. The Quantum Insider, "University of Nottingham, Phasecraft and QuEra Awarded £1 Million for Drug Development Research", 2024-04-13 (trade press reproducing a university press release). thequantuminsider.com(accessed 2026-11-18)
  8. Quantum Computing Report, "POLARISqb Secures DARPA Funding to Propel Quantum Computing Applications in Drug Design", 2024 (trade press; the page carries no date in the text read; the Landscape's evidence record dates it March 2024; no contract amount stated). quantumcomputingreport.com (accessed 2026-11-18)
  9. NIH RePORTER, project search. reporter.nih.gov (listed as a data source, not opened for this Brief)
  10. SEC EDGAR, full-text search. sec.gov (listed as a data source; not run for this Brief)
  11. Europe PMC REST API. ebi.ac.uk (listed as a data source; review abstracts were read through it for other claims in this Brief, 2026-11-18; not searched for this Junction)
  12. ClinicalTrials.gov, study search. clinicaltrials.gov (listed as a data source; not searched for this Brief)